Meseci Elif, Naki Mehmet Murat
Clinic of Obstetrics and Gynecology, Acıbadem Kozyatağı Hospital, İstanbul, Turkey
Department of Obstetrics and Gynecology, Acıbadem University School of Medicine, İstanbul, Turkey
J Turk Ger Gynecol Assoc. 2019 Aug 28;20(3):154-164. doi: 10.4274/jtgga.galenos.2019.2019.0061. Epub 2019 Jul 12.
To determine the clinical and pathologic characteristics, prognostic factors, surgical practice, adjuvant therapies, and survival outcomes of patients with uterine sarcoma diagnosed and treated in our institution.
Patients diagnosed and treated for uterine sarcomas at our institution from 2009 to 2017 were retrospectively evaluated. All histologic slides from the specimens underwent a thorough pathologic review by a gynecologic pathologist. The following variables were assessed: age, family history of cancer, smoking status, age of menarche, parity, age at first delivery, related symptoms, clinical staging, histologic type, treatment received, disease-free period, and the time and site of recurrence, as well as treatment of the latter and overall survival.
Ten patients were diagnosed as having leiomyosarcoma, a further 10 patients had malignant mixed mullerian tumors, and five had endometrial stromal sarcoma; the remaining nine patients had other tumors. At the end of our study, 12 (35.3%) patients were alive and in remission, four (11.8%) were alive with disease, 10 (29.4%) were lost to follow-up, and eight (23.5%) had died. The mean survival time was 80.92 months, and the 2-year survival rate was 75.6%. We found that survival was significantly shorter in the presence of lymph node involvement, residual tumor, and recurrence.
This study serves to inform physicians about the outcome of various uterine sarcomas that were diagnosed and managed at our center. We found that 35.3% of our patients were alive and in remission, 11.8% were alive with disease, 29.4% were lost to follow-up, and 23.5% of patients died.
确定在我们机构诊断和治疗的子宫肉瘤患者的临床和病理特征、预后因素、手术方式、辅助治疗及生存结果。
对2009年至2017年在我们机构诊断和治疗子宫肉瘤的患者进行回顾性评估。所有标本的组织学切片均由妇科病理学家进行全面的病理复查。评估以下变量：年龄、癌症家族史、吸烟状况、初潮年龄、产次、首次分娩年龄、相关症状、临床分期、组织学类型、接受的治疗、无病生存期、复发时间和部位，以及复发后的治疗和总生存期。
10例患者被诊断为平滑肌肉瘤，另外10例为恶性混合苗勒管肿瘤，5例为子宫内膜间质肉瘤；其余9例患者患有其他肿瘤。在我们的研究结束时，12例（35.3%）患者存活且病情缓解，4例（11.8%）患者带瘤存活，10例（29.4%）失访，8例（23.5%）死亡。平均生存时间为80.92个月，2年生存率为75.6%。我们发现，存在淋巴结受累、残留肿瘤和复发时，生存期明显缩短。
本研究旨在让医生了解在我们中心诊断和管理的各种子宫肉瘤的结局。我们发现，35.3%的患者存活且病情缓解，11.8%的患者带瘤存活，29.4%失访，23.5%的患者死亡。
